Dimerix Limited
ASX: DXB
Dimerix Limited invests in the research and development of biopharmaceutical drugs. Its focus includes advancing the DMX-200 candidate for renal and respiratory conditions, as well as progressing the DMX-700 pre-clinical asset for Chronic Obstructive Pulmonary Disease. Established on May 13, 1975, the company is headquartered in Melbourne, Australia.
*Target
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
PG Weekly Pick
A$100.00
Already a subscriber?
Sign in to read this report.
Required subscription
PG Weekly Pick
Receive one high-conviction ASX stock idea every week, backed by detailed research, risk analysis, and a clear investment thesis designed to help you focus on quality opportunities.
- ✓ One Premium ASX Stock Pick Weekly
- ✓ Delivered Every Friday
- ✓ Buy / Hold / Sell Guidance & Risk Rating
- ✓ Full Historical Pick Access
A$100.00/ 1 months
Risk:High
Subscribe Now →